These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8571943)

  • 1. Platelet activation and thrombosis: studies in a patient with essential thrombocythemia.
    Nurden P; Bihour C; Smith M; Raymond JM; Nurden AT
    Am J Hematol; 1996 Jan; 51(1):79-84. PubMed ID: 8571943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa.
    Frojmovic MM; Kasirer-Friede A; Goldsmith HL; Brown EA
    Thromb Haemost; 1997 Mar; 77(3):568-76. PubMed ID: 9066012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of activated platelets by flow cytometry].
    Kohmura C; Hayashi Y; Ikeda H
    Rinsho Byori; 1999 May; 47(5):447-52. PubMed ID: 10375966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling.
    Marwali MR; Hu CP; Mohandas B; Dandapat A; Deonikar P; Chen J; Cawich I; Sawamura T; Kavdia M; Mehta JL
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1324-32. PubMed ID: 17538005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in platelet membrane glycoproteins before bone marrow transplantation and after engraftment--a pilot study.
    Neumeister P; Hiller E; Gawaz M; Holler E; Kolb HJ; Sill H; Pihusch R; Mempel W; Wittmann G; Salat C
    Eur J Med Res; 1998 Oct; 3(10):465-9. PubMed ID: 9753703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry.
    Tomer A
    J Biol Regul Homeost Agents; 2004; 18(2):172-7. PubMed ID: 15471223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human platelet IgG Fc receptor associated with membrane glycoprotein.
    Shido K; Ahmad G; Hsu L; Kamiyama M
    J Clin Lab Immunol; 1995; 46(1):1-11. PubMed ID: 9363587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].
    Khaspekova SG; Vyzova TV; Lukin VV; Tikhomirov OIu; Berndt M; Kouns W; Mazurov AV
    Biokhimiia; 1996 Mar; 61(3):412-28. PubMed ID: 8724599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets.
    Patel Y; Rahman S; Siddiqua A; Wilkinson JM; Kakkar VV; Authi KS
    Thromb Haemost; 1998 Jan; 79(1):177-85. PubMed ID: 9459345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
    Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
    Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation.
    Goto S; Tamura N; Sakakibara M; Ikeda Y; Handa S
    Platelets; 2001 Nov; 12(7):406-14. PubMed ID: 11674857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
    Labiós M; Martínez M; Gabriel F; Guiral V; Martínez E; Aznar J
    Thromb Res; 2005; 115(4):263-70. PubMed ID: 15668185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.